82 F.4th 564
7th Cir.2023Background
- Inventors (former CelgenTek shareholders including Dr. Thomas Russell) sold CelgenTek to Zimmer in Sept. 2016; Zimmer paid $17.1M and the Inventors retained earnout rights (1.5%–6% of net sales through 2033) tied to specified "earnout products."
- The stock purchase agreement required Zimmer to use commercially reasonable efforts (as defined in the contract) to sell the earnout products, but explicitly tied that standard to Zimmer’s own ordinary business practices and portfolio context and disclaimed fiduciary duties or any guarantee of earnouts.
- Inventors alleged Zimmer paid only ~$130,000 in earnouts through 2019 and identified 21 specific actions/inactions (e.g., staff cuts, halted trials, expired CE marks, stopped manufacturing, terminated distribution agreements, reduced communications) as breaches of the commercially reasonable efforts obligation.
- Plaintiffs sued in Tennessee; case transferred to Northern District of Indiana per the agreement’s forum-selection clause. Plaintiffs amended to plead a single breach-of-contract claim asserting failure to use commercially reasonable efforts.
- District court dismissed under Rule 12(b)(6), holding plaintiffs failed to plead facts showing Zimmer deviated from its own ordinary-course practices (the contract’s comparison baseline) or that performance should be judged by objective/industry standards; it also denied leave to amend as futile.
- Seventh Circuit affirmed: the complaint did not plead facts comparing Zimmer’s conduct to Zimmer’s comparable internal efforts or the full business/regulatory context required by the contract, and denial of leave to amend was not an abuse of discretion.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether the complaint plausibly alleges breach of the contract duty to use commercially reasonable efforts to sell earnout products | Inventors: 21 alleged acts/omissions show Zimmer did not use commercially reasonable efforts and acted to protect other business segments rather than commercialize the products | Zimmer: Contract defines the standard by reference to Zimmer’s own ordinary practices and portfolio context; plaintiffs only second-guess permissible business decisions and fail to allege deviation from Zimmer’s usual standard | Court: Dismissed — plaintiffs failed to allege a comparator (Zimmer’s conduct toward similar products) or facts showing Zimmer departed from its ordinary-course practices or considered the full business/regulatory context required by the contract |
| Whether the district court abused its discretion by denying leave to amend a second time | Inventors: Should be allowed to amend to add more factual detail; little prejudice to Zimmer | Zimmer: Additional amendment would be futile; district court acted within discretion | Court: Affirmed denial — plaintiffs offered no concrete description of cures; further amendment would be futile and would prejudice Zimmer |
Key Cases Cited
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (U.S. 2007) (plausibility pleading standard)
- Swanson v. Citibank, N.A., 614 F.3d 400 (7th Cir. 2010) (notice pleading and factual plausibility discussion)
- Berg v. Berg, 170 N.E.3d 224 (Ind. 2021) (elements of breach of contract under Indiana law)
- Hartman v. BigInch Fabricators & Constr. Holding Co., Inc., 161 N.E.3d 1218 (Ind. 2021) (contract interpretation: apply plain meaning when unambiguous)
- Stant USA Corp. v. Factory Mut. Ins. Co., 61 F.4th 524 (7th Cir. 2023) (standard of appellate review for Rule 12(b)(6))
- MAO-MSO Recovery II, LLC v. State Farm Mut. Auto. Ins. Co., 935 F.3d 573 (7th Cir. 2019) (district court discretion to deny leave to amend when amendment is futile)
- Nowlin v. Pritzker, 34 F.4th 629 (7th Cir. 2022) (de novo review of futility legal determinations on appeal)
- Brant v. Schneider Nat’l, Inc., 43 F.4th 656 (7th Cir. 2022) (clarifying plausibility threshold under Rule 8)